Comparative immune responses of patients with chronic pulmonary diseases during the 2-year period after pneumococcal vaccination

Clinical and Vaccine Immunology

Volumn 14, Issue 2, 2007, Pages 139-145

  Chen, Meng ^a   Hisatomi, Yuki ^a   Furumoto, Akitsugu ^a   Kawakami, Kenji ^b   Masaki, Hironori ^c   Nagatake, Tsuyoshi ^a   Sueyasu, Yoshiko ^d   Iwanaga, Tomoaki ^e   Aizawa, Hisamichi ^d   Oishi, Kazunori ^a,f  

^a NAGASAKI UNIVERSITY   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^c Tagami Hospital   (Japan)

^d KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e FUKUOKA HIGASHI MEDICAL CENTER   (Japan)

^f OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; PNEUMOCOCCUS VACCINE;

ADULT; AGED; ANTIBODY RESPONSE; ARTICLE; CHRONIC LUNG DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; IMMUNE RESPONSE; MALE; PRIORITY JOURNAL; SEROTYPING; STREPTOCOCCUS PNEUMONIAE; VACCINATION;

ANTIBODIES, BACTERIAL; CHRONIC DISEASE; HUMANS; IMMUNITY, NATURAL; IMMUNOGLOBULIN G; LUNG DISEASES; PNEUMOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; TIME FACTORS;

EID: 33947169913     PISSN: 15566811     EISSN: None     Source Type: Journal    
DOI: 10.1128/CVI.00336-06     Document Type: Article

References (32)

1. Alfageme, I., R. Vazquez, N. Reyes, J. Munos, A. Fernandez, M. Hernandez, M. Merino, J. Perez, and J. Lima. 2006. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax 61:189-195.
2. Anttila, M., J. Eskola, H. Ahman, and H. Kayhty. 1998. Avidity of IgG for Streptococcus pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal conjugates and boosted with polysaccharide or conjugate vaccines. J. Infect. Dis. 177:1614-1621.
3. Baquero, F. 1995. Pneumococcal resistance to β-lactam antibiotics: a global geographic overview. Microb. Drug Resist. 1:115-120.
4. Bogaert, D., R. de Groot, and P. W. M. Hermans. 2004. Streptococcus pneumoniae colonization: the key to pneumococcal disease. Lancet Infect. Dis. 4:144-154.
5. Bogaert, D., P. van der Valk, R. Ramdin, M. Sluijter, E. Monninkhof, R. Hendrix, R. de Goot, and P. W. M. Hermans. 2004. Host-pathogen interaction during pneumococcal infection in patients with chronic obstructive pulmonary disease. Infect. Immun. 72:818-823.
6. Brandao, A. P., T. C. de Oliveira, M. C. de Cunto Brandileone, J. E. Goncalves, T. I. Yara, and V. Simonsen. 2004. Persistence of antibody response to pneumococcal capsular polysaccharides in vaccinated long term-care residents in Brazil. Vaccine 23:762-768.
7. Bruyn, G. A., P. S. Hiemstra, A. Matze-van der Lans, and R. van Furth. 1990. Pneumococcal anticapsular antibodies in patients with chronic cardiovascular and obstructive lung disease in The Netherlands. J. Infect. Dis. 162:1192-1194.
8. Butler, J. C., E. D. Shapiro, and G. M. Carlone. 1999. Pneumococcal vaccines: history, current status, and future directions. Am. J. Med. 107(1A):69S-76S.
9. Centers for Disease Control and Prevention. 1997. Prevention of pneumococcal disease: recommendations of the advisory committee on immunization practices (ACIP). Morb. Mortal. Wkly. Rep. 46:1-24.
10. Concepcion, N. F., and C. E. Frasch. 2001. Pneumococcal type 22F polysaccharide absorption improves the specificity of a pneumococcal- polysaccharide enzyme-linked immunosorbent assay. Clin. Diagn. Lab. Immunol. 8:266-272.
11. Davis, L. A., C. A. P. Aranda, G. Schiffman, and C. L. Cristianson. 1987. Pneumococcal infection and immunologic response to pneumococcal vaccine in chronic obstructive pulmonary disease. Chest 92:204-212.
12. de Roux, A., N. Schmidt, M. Rose, S. Zielen, M. Pletz, and H. Lode. 2004. Immunogenity of the pneumococcal polysaccharide vaccine in COPD patients. The effect of systemic steroids. Respir. Med. 98:1187-1194.
13. Fedson, D. S., and J. A. G. Scott. 1999. The burden of pneumococcal disease among adults in developed and developing countries: what is and is not known. Vaccine 17:S11-S18.
14. Fedson, D. S., D. M. Musher, and J. Eskola. 1998. Pneumococcal vaccine, p. 553-607. In S. Plotkin and W. A. Orenstein (ed.), Vaccines, 3rd ed. W. B. Saunders Co., Philadelphia, PA.
15. Feikin, D. R., K. P. Klugman, R. R. Facklam, E. R. Zell, A. Schuchat, and C. G. Whitney for the Active Bacterial Core Surveillance/Emerging Infections Program Network. 2005. Increased prevalence of pediatric pneumococcal serotypes in elderly adults. Clin. Infect. Dis. 41:481-487.
16. Inoue, M., N. Y. Lee, S. W. Hong, K. Lee, and D. Felmingham. 2004. PROTEKT 1999-2000: a multicenter study of the antibiotic susceptibility of respiratory tract pathogens in Hong Kong, Japan and South Korea. Int. J. Antimicrob. Agents 23:44-51.
17. Lahood, N., S. S. Emerson, P. Kumar, and R. U. Sorensen. 1993. Antibody levels and response to pneumococcal vaccine in steroid-dependent asthma. Ann. Allergy 70:289-294.
18. Musher, D. M., A. J. Chapman, A. Goree, S. Jonsson, D. Briles, and R. E. Baughn. 1986. Natural and vaccine-related immunity to Streptococcus pneumoniae. J. Infect. Dis. 154:245-256.
19. Oishi, K., H. Yoshimine, H. Watanabe, K. Watanabe, S. Tanimura, K. Kawakami, A. Iwagaki, H. Nagai, H. Goto, S. Kudoh, T. Kuriyama, Y. Fukuchi, T. Matsushima, K. Shimada, K. Matsumoto, and T. Nagatake. 2006. Drug-resistant genes and serotypes of pneumococcal strains of community-acquired pneumonia among adults in Japan. Respirology 11:429-436.
20. Romero-Steiner, S., D. M. Musher, M. S. Cetron, L. B. Paris, J. E. Groover, A. E. Fiore, B. D. Olikaytis, and G. M. Carlone. 1999. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clin. Infect. Dis. 29:281-288.
21. Rubins, J. B., A. K. G. Puri, J. Loch, D. Charboneau, R. MacDonald, N. Opstad, and E. N. Janoff. 1998. Magnitude, duration, quality, and function of pneumococcal vaccine responses in elderly adults. J. Infect. Dis. 178:431-440.
22. Saito, W., H. Nagai, J. Suzuki, K. Masuda, A. Tamura, N. Nagayama, S. Akagawa, Y. Kawabe, K. Machida, A. Kurashima, H. Yotsumoto, T. Saito, T. Arai, and N. Okabe. 2005. Capsular polysaccharide antibodies after pneumococcal polysaccharide vaccination in patients with chronic respiratory disease. Nihon Kokyuki Gakkai Zasshi 43:277-282.
23. Sankilampi, U., P. O. Honkanen, A. Bloigu, and M. Leinonen. 1997. Persistence of antibodies to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 176:1100-1104.
24. Sankilampi, U., P. O. Honkanen, A. Bloigu, E. Herva, and M. Leinonen. 1996. Antibody response to pneumococcal capsular polysaccharide vaccine in the elderly. J. Infect. Dis. 173:387-393.
25. Sethi, S. 2004. New developments in the pathogenesis of acute exacerbation of chronic obstructive pulmonary disease. Curr. Opin. Infect. Dis. 17:113-119.
26. Shapiro, E. D., A. T. Berg, R. Austrian, D. Schroeder, V. Parcells, A. Margolis, R. K. Adair, and J. D. Clemens. 1991. The protective efficacy of polyvalent pneumococcal polysaccharide vaccine. N. Engl. J. Med. 325:1453-1460.
27. Simberkoff, M. S., A. P. Cross, M. Al-Ibrahim, A. L. Baltch, P. J. Geiseler, J. Nadler, A. S. Richmond, R. P. Smith, G. Schiffman, and D. S. Shepard. 1986. Efficacy of pneumococcal vaccine in high-risk patients. Results of a Veterans Administration cooperative study. N. Engl. J. Med. 315:1318-1327.
28. Song, J. H., N. Y. Lee, S. Ichiyama, R. Yoshida, Y. Hirakata, F. Wang, A. Chongthaleong, N. Aswapokee, C. Chiu, M. K. Lalitha, K. Thomas, J. Perera, T. T. Yee, F. Jamal, U. C. Warsa, B. X. Vinh, M. R. Jacobs, P. C. Appelbaum, C. H. Pai, and the ANSORP Study Group. 1999. Spread of drug-resistant Streptococcus pneumoniae in Asian countries: Asian Network for Surveillance of Resistant Pathogens (ANSORP) study. Clin. Infect. Dis. 28:1206-1211.
29. Wernette, C. M., C. E. Frasch, D. Madore, G. Carlone, D. Goldblatt, B. Plikaytis, W. Benjamin, S. A. Quataert, S. Hildreth, D. J. Sikkema, H. Kayhty, I. Jonsdottir, and M. H. Nahm. 2003. Enzyme-linked immunosorbent assay for quantitation of human antibodies to pneumococcal polysaccharides. Clin. Diagn. Lab. Immunol. 10:514-519.
30. Williams, J. H., Jr., and K. M. Moser. 1986. Pneumococcal vaccine and patients with chronic lung diseases. Ann. Intern. Med. 104:106-109.
31. World Health Organization Pneumococcal Serology Reference Laboratories. 9 June 2004, accession date. Training manual for enzyme linked immunosorbent assay for quantitation of Streptococcus pneumoniae serotype specific IgG (Pn PS ELISA). World Health Organization, Geneva, Switzerland. http://www.vaccine.uab.edu/ELISA%20Protocol.pdf.
32. Wuorimaa, T., R. Dagan, M. Vakevainen, F. Bailleux, R. Haikala, M. Yaich, J. Eskola, and H. Kayhty. 2001. Avidity and subclasses of IgG after immunization of infants with an 11-valent pneumococcal conjugate vaccine with or without aluminum adjuvant. J. Infect. Dis. 184:1211-1215.